Overview

Expanded Access Study With Peginterferon Alfa-2a (Pegasys) in Participants With Chronic Myelogenous Leukemia (CML)

Status:
Completed

Trial end date:
2010-11-01

Target enrollment:
0

Participant gender:
All

Summary

This study will evaluate the efficacy, safety and tolerability of long-term use of peginterferon alfa-2a in participants with CML who have previously participated in peginterferon alfa-2a study ML16544 (NCT number not available), NO16006 (NCT number not available) or ML17228 (NCT number not available) and treating physician has decided to continue treatment with peginterferon alfa-2a within the frame of another clinical study.

Phase:

Phase 3

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Hoffmann-La Roche

Treatments:

Interferon-alpha
Peginterferon alfa-2a

Criteria

Inclusion Criteria:

- Participants with CML

- Previous participation in studies: ML16544, NO16006 or ML17228; for which the treating
physician recommends a continuation of the study drug according to defined minimal
criteria

Exclusion Criteria:

- Major protocol violator in the participated study prior to participation in this study